Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Use of anti-PD-1 antibody in treatment of tumors

A technology of PD-1 and antibody, which is applied in the field of melanoma and solid tumor treatment, and can solve problems such as poor efficacy

Active Publication Date: 2020-03-17
SHANGHAI JUNSHI BIOSCI
View PDF4 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Retrospective study by Cho, J. et al., Invest New Drugs (2016), 34:677-84 shows that immunotherapy is less effective in ALM and MM compared with CSD melanoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of anti-PD-1 antibody in treatment of tumors
  • Use of anti-PD-1 antibody in treatment of tumors
  • Use of anti-PD-1 antibody in treatment of tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0191] Example 1: Clinical research on anti-PD-1 antibody monotherapy for tumor treatment

[0192] Inclusion Criteria: Eligible subjects must (1) be between the ages of 18 and 70, (2) have metastatic melanoma or urological cancer, (3) be refractory to standard systemic therapy, (4) ) ECOG score of 0 or 1, (5) no history of autoimmune disease or persistent infection, (6) not received any immunotherapy before.

[0193] Subjects must have evaluable lesions according to RECIST v 1.1 standards, and are not allowed to use anti-tumor drug therapy, systemic steroid drug therapy or have not used anti-CTLA4, anti-PD-1, anti-PD-L1 antibody therapy. The demographic data of the enrolled subjects are shown in Table 1.

[0194] Table 1: Demographic data of enrolled subjects

[0195]

[0196] Test drug: anti-PD-1 antibody toripalimab (WO2014206107).

[0197] There are three anti-PD-1 antibody dose groups in this trial, namely: 1mg / kg (n=15), 3mg / kg (n=15) and 10mg / kg (n=6), administered...

Embodiment 2

[0237] Example 2: Research on the correspondence between natural killer cells (NK) and anti-PD-1 antibody therapeutic effect on tumors

[0238] During the course of the clinical trial described in Example 1, the frequency and activation status (by CD45RA staining) of T lymphocytes in whole blood were assessed. Anti-PD-1 antibody against activated CD8 in the peripheral blood of a single subject + The frequency of T lymphocytes had little effect. Such as Figure 5 As shown, in the group with PFS greater than 250 days, CD8 + Subjects with high cell activation rates were enriched. Before toripalimab treatment, all subjects activated CD8 + The average percentage is 65%. 4 / 5 durable responders (PFS >300 days) were found to have more than 80% activated CD8 in peripheral blood + (total CD8 + cells) and more than 26% CD3 - CD16 + CD54 + NK cells (total monocytes); in contrast activated CD8 in all subjects + The average percentages of T cells and NK cells were 65% and 20%, re...

Embodiment 3

[0239] Example 3: Research on the correlation between biomarkers and clinical efficacy

[0240] By performing PD-L1CD8 double IHC staining on tumor biopsy specimens of 28 patients, the correlation between tumor histology and anti-PD-1 antibody clinical efficacy was analyzed. Rabbit anti-human PD-L1 antibody SP142 from Roche and anti-CD8 clone 4B11 were used. PD-L1 positive status was defined as the presence of ≥1% membrane staining intensity of tumor cells.

[0241] Such as Figure 6 and Figure 7 As shown, subjects with positive PD-L1 expression in tumor biopsies benefited more from TORIPALIMAB treatment than subjects with negative PD-L1 expression (43.8% ORR, 62.5 DCR vs. 0% ORR, 50% DCR) . The subpopulation with high PD-1 expression (>50%) responded best to TORIPALIMAB treatment, with an ORR of 57.1% and a DCR of 71.4%. Notably, all ORR (CR+PR) subjects were dual positive for PD-L1 and TIL. Co-localization of TILs and PD-L1+ cells was found in tumor biopsies, and 93.8...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of an anti-PD-1 antibody in the treatment of tumors. The invention also relates to use of a reagent for detecting the state of CD8 + T cells and / or NK cells inperipheral blood or a reagent for detecting EMSY genes in a detection kit for predicting the treatment effect of a tumor patient on the anti-PD-1 antibody and / or an antigen binding fragment thereof.

Description

technical field [0001] The present invention relates to the use of anti-PD-1 antibody in treating tumors. Specifically, the present invention relates to the use of anti-PD-1 antibodies in the treatment of solid tumors, especially melanoma; and the use of anti-PD-1 antibodies in the preparation of drugs for the treatment of solid tumors, especially melanoma; and the use of biological A method for predicting the curative effect of an anti-PD-1 antibody in the treatment of a solid tumor by a marker; and the use of a combination therapy or composition comprising the anti-PD-1 antibody in the treatment of a solid tumor. Background technique [0002] Immune escape is one of the hallmarks of cancer. Ahmadzadeh, M. et al., Blood, 114:1537-44 disclosed that tumor-specific T lymphocytes often exist in the tumor microenvironment, draining lymph nodes and peripheral blood, but due to the immunosuppressive mechanism network existing in the tumor microenvironment, their Often the progre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P35/00G01N33/574G01N33/577G01N33/68C12Q1/6886
CPCA61K45/06A61K2039/505A61P35/00A61K2039/876C07K16/2818
Inventor 姚盛冯辉武海
Owner SHANGHAI JUNSHI BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com